Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05984277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Study acronym: eVOLVE-Lung02
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Apr 24, 2028 → Feb 28, 2029
Enrollment reduced 25% 1200 → 895 participants
See other at-risk trials from AstraZeneca

Record History

  1. Trial sites reduced: 247 → 231 locations Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026 · Completion moved earlier from Feb 28, 2029 to Nov 12, 2027 · Eligibility criteria expanded, about 12 words · 1 more Show 4 more changesShow less
    • Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026
    • Completion moved earlier from Feb 28, 2029 to Nov 12, 2027
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Primary completion pushed from Apr 24, 2028 to Feb 28, 2029 Enrollment reduced: 1200 → 895 participants · Trial sites reduced: 256 → 247 locations · Completion date: Mar 23, 2029 to Feb 28, 2029v20 Show 3 more changesShow less
    • Enrollment reduced: 1200 → 895 participants
    • Trial sites reduced: 256 → 247 locations
    • Completion date: Mar 23, 2029 to Feb 28, 2029
  3. Re-verified, no change to tracked fieldsv19
  4. Trial status: Recruiting to Active, Not Recruiting Study sites: 302 to 256v18 Show 1 more changeShow less
    • Study sites: 302 to 256
  5. Study sites: 299 to 302v17
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 298 to 299v16
  2. Enrollment target: 900 to 1200 Study sites: 296 to 298 · Primary completion date: May 30, 2028 to Apr 24, 2028 · Completion date: May 16, 2029 to Mar 23, 2029 · 1 morev15 Show 4 more changesShow less
    • Study sites: 296 to 298
    • Primary completion date: May 30, 2028 to Apr 24, 2028
    • Completion date: May 16, 2029 to Mar 23, 2029
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 289 to 296v14
  4. Study sites: 286 to 289v13
  5. Study sites: 280 to 286v12
  6. Study sites: 254 to 280v11
  7. Study sites: 242 to 254v10
  8. Study sites: 234 to 242v9
  9. Study sites: 231 to 234v8
  10. Study sites: 226 to 231v7
  11. Study sites: 224 to 226v6
  12. Study sites: 200 to 224v5
  13. Study sites: 194 to 200 Eligibility criteria expanded, about 9 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  14. Study sites: 132 to 194v3
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 52 to 132 · Start date changed from estimate of Nov 30, 2023 to Oct 24, 2023v2 Show 2 more changesShow less
    • Study sites: 52 to 132
    • Start date changed from estimate of Nov 30, 2023 to Oct 24, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Trial Details
NCT Number NCT05984277
Lead Sponsor AstraZeneca
Conditions Metastatic Non-small Cell Lung Cancer
Enrollment 895 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov